Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer
2016
Differential Enhancement of Breast Cancer Cell Motility and Metastasis by Helical and Kinase Domain Mutations of Class IA Phosphoinositide 3-Kinase
2009
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2016
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype
2016 StandoutNobel
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells
2008
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
The CD44+/CD24-phenotype is enriched in basal-like breast tumors
2008
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
2011 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
p85 Associates with Unphosphorylated PTEN and the PTEN-Associated Complex
2009
Triple-Negative Breast Cancer
2010 Standout
Determining True HER2 Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2 Targeted Therapy
2011
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer
2010
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade
2009
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
2009 Standout
Breast cancer
2016 Standout
Diagnosing and exploiting cancer's addiction to blocks in apoptosis
2008
Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect
2016
Molecular mechanisms of drug resistance
2005
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
2012
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab
2011
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts
2005
Cancer drug resistance: an evolving paradigm
2013 Standout
Nasopharyngeal carcinoma
2019 Standout
HER2 genetic heterogeneity in breast carcinoma
2011
Growth factor stimulation induces a distinct ERα cistrome underlying breast cancer endocrine resistance
2010
GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME
2008
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
P21Cip1/WAF1 expression is strongly associated with HPV-positive tonsillar carcinoma and a favorable prognosis
2009
The landscape of long noncoding RNAs in the human transcriptome
2015 Standout
The role of PTEN signaling perturbations in cancer and in targeted therapy
2008
WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis
2009
A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma
1999
The cancer biomarker problem
2008 Nature
Wnt/β-Catenin Signaling and Disease
2012 Standout
p21 in cancer: intricate networks and multiple activities
2009 Standout
An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors
2008 Standout
Systemic Lupus Erythematosus
2011 Standout
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
2009
Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia
2010
Malignant Gliomas in Adults
2008 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
pROC: an open-source package for R and S+ to analyze and compare ROC curves
2011 Standout
How to calculate the dose of chemotherapy
2002
Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer
2015
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
2013 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
GOBO: Gene Expression-Based Outcome for Breast Cancer Online
2011
No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study
2015
Angiogenesis inhibitors in the management of breast cancer
2009
Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
2005
The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours
2006
Primary brain tumours in adults
2012 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
2007
The functions and regulation of the PTEN tumour suppressor
2012 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Idiopathic pulmonary fibrosis
2011 Standout
The PI3K Pathway in Human Disease
2017 Standout
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Radiation therapy and tamoxifen after breast-conserving surgery: Updated results of a 2×2 randomised clinical trial in patients with low risk of recurrence
2009
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
2017 Standout
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
2012 StandoutNobel
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
2001
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
2009
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
2009 Standout
Small-sample precision of ROC-related estimates
2010
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Breast Cancer Treatment
2019 Standout
Topoisomerase levels determine chemotherapy response in vitro and in vivo
2008
A Combined Shotgun and Targeted Mass Spectrometry Strategy for Breast Cancer Biomarker Discovery
2015
What is principal component analysis?
2008 Standout
Cancer Genome Landscapes
2013 StandoutScience
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer
2003
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
A systemic lupus erythematosus gene expression array in disease diagnosis and classification: a preliminary report
2010
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial
2009
Identification of molecular apocrine breast tumours by microarray analysis
2005
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Chemical Glycoproteomics
2016 StandoutNobel
Dose translation from animal to human studies revisited
2007 Standout
Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance
2008
Works of Per Malmström being referenced
Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-Negative Breast Carcinoma
2007
Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes
2012
Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II:I
2007
A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4
1991
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
2000
Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer
2008
TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer
2006
Reoperation for malignant astrocytomas: Personal experience and a review of the literature
1993
Symptoms 10–17 years after breast cancer radiotherapy data from the randomised SWEBCG91-RT trial
2010
The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer
2009
Grading Breast Cancer Tissues Using Molecular Portraits
2013
Topoisomerase IIα Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu–Amplified Breast Cancer: Scandinavian Breast Group Trial 9401
2006
The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.
2002
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
2007
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
2000